Navigation Links
Two NIH initiatives launch intensive efforts to find roots of common diseases

esearch exemplifies the aim Congress had in mind when it established the Foundation for the National Institutes of Health to support the mission of NIH," said John E. Porter, Vice Chairman of the foundation's Board of Directors. "Through the financial support of the private sector, NIH will now be able to launch into this exciting initiative immediately. Moreover, the interaction of scientists from the public and the private sector dramatically increase the likelihood that this initiative will get off to a quick and efficient start that will genuinely produce important advances for all patients."

Genetic Factors

The genetic analysis of both GAIN and GEI will focus on the alternative spellings ?called single nucleotide polymorphisms or SNPs ?that normally occur in the order of the 3 billion DNA base pairs or letters that make up a person's genome. SNPs are like single-letter misspellings of a word. Most of these genetic variations are biologically meaningless. But a small fraction of these SNPs alter the function of a gene ?often only slightly. The combination of many slightly altered genes may significantly increase the risk of a specific disease, but identifying such a complex set of genetics changes is challenging. Finding these disease-causing variants is one of the highest priorities of current biomedical research.

"Virtually all diseases have a hereditary component, transmitted from parent to child through the three billion DNA letters that make up the human genome," said Francis S. Collins, M.D., Ph.D., Director of the National Human Genome Research Institute at NIH and chairman of the GAIN Steering Committee and co-chairman of the NIH Coordinating Committee for GEI. "But progress in identifying the genetic factors that influence health or disease, or even the response to treatment, is difficult. Both initiatives promise to rapidly identify the myriad genes in an individual that, taken together, contribute to an increased risk o
'"/>

Source:NIH/National Human Genome Research Institute


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
2. UNC launches study of liver injury caused by drugs
3. Roche clinical trial registry and results database launched
4. First technology to remove prions that cause vCJD from blood launched
5. DOE JGI launches IMG public online microbial genome data clearinghouse
6. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
7. NIH launches comprehensive effort to explore cancer genomics
8. Virginia Bioinformatics Institutes launches microbial database
9. BioMed Central launches Biology Direct
10. Sandia work launched on space shuttle shows live cells influence growth of nanostructures
11. PLoS ONE is launched by the Public Library of Science
Post Your Comments:
Breaking Biology News(10 mins):Tropical birds waited for land crossing between North and South America: UBC study 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 477 percent of European pigs are castrated without anesthetic 2Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 1Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 2Smokers Twice As Likely to Get TB 55170 1Smokers Twice As Likely to Get TB 55170 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10